INVESTORS

Stock Information

State of Linical’s Stock

AS OF MARCH 31, 2024
TOTAL NO. OF AUTHORIZED SHARES
49,600,000
TOTAL NO. OF ISSUED SHARES
24,740,000
NO. OF SHAREHOLDERS
5,520

Major Shareholders

AS OF MARCH 31, 2024
NAME
NO. OF SHARES
PROPORTION OF SHARES (%)
HATANO CO. LTD.

4,500 K

19.93

TAKAHASHI CO. LTD.

1,994

8.83

KEIGO TSUJIMOTO

1,024

4.53

SAKAMOTO CO. LTD.

810

3.58

KAZUHIRO HATANO

742

3.28

AKIHIRO TAKAHASHI

741

3.28

ISAO SAKAMOTO

735

3.25

KOICHI TAKAGI

720

3.18

JUN KAWAI

600

2.65

MASAYA MIYAZAKI

600

2.65

NOTE: Linical owns 2,153,564 shares in its own stock, separate to the shareholdings outlined above.

Want to learn more? Contact the Linical Investor Relations Team.

Successful clinical trials start with Linical.

Don’t let the complex clinical development journey hold you back. With Linical, you can overcome obstacles, save valuable time and money, and reach your goals. 

01 Request a proposal

We start by listening to your needs and understanding your goals to ensure we’re the right CRO for you.

02 Get a plan for success

We propose solutions that proactively tackle obstacles, optimize your trial design, and position you for success every step of the way.

03 Execute with confidence

We’ll guide you through each phase of the process, offering personalized support and a full range of services to help you achieve a successful trial. We are not a “one size fits all” CRO.

cta-img (2)